Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

rm Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the outcome of ongoing clinical trials, the status and timing or regulatory approvals for Pharmion's product candidates; the impact of competition from other products under development by Pharmion's competitors; the regulatory environment and changes in the health policies and structure of various countries; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; Pharmion's ability to successfully acquire rights to, develop and commercialize additional pharmaceutical products; failure of third-party manufacturers to produce the product volumes required on a timely basis, fluctuations in currency exchange rates, and other factors that are discussed in Pharmion's filings with the U.S. Securities and Exchange Commission, including those discussed in the "Risk Factors" section of Pharmion's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

PHARMION CORPORATION

CONSOLIDATED FINANCIAL RESULTS

(In thousands, except for per share amounts)

Unaudited

Three Months Ended Twelve Months Ended<
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... (Amex: NBS ),announced today that the new Southern Florida ... Miami, is targeted to open in,September. The center is being ... of this center, NeoStem has secured a key geographic,stronghold in ... as well as a,growing sophisticated South American presence., Chester ...
... Techne Corporation,s,(Nasdaq: TECH ) consolidated net earnings ... $27.3 million or $.70 per diluted share compared,with $22.9 ... ended June 30,2007. For the fiscal year ended June ... million or $2.64 per diluted share,compared with $85.1 million ...
... Life Sciences Inc.,(TSX:PLI) ("ProMetic") announces today that ... integrated, U.S.-based, biotechnology company with respect to,the ... in ProMetic,s Protein Technology Division., In ... as well as,on-going royalties on sales of ...
Cached Biology Technology:NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide 2NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide 3Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 2Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 3Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 4Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 5Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008 6Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment 2Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment 3
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... smoke for a prolonged period of time and in ... even in women who never smoked cigarettes themselves. ... could increase risk of breast cancer is one that ... at the Northern California Cancer Center,s Berkeley office. "While ...
... forest,s woodland herb population has shown that climate may ... logging, according to Purdue University research. Despite heavy ... ago, the distribution of trillium plants on the secondary ... Michael Jenkins, a Purdue assistant professor of forestry and ...
... Georgia College of Veterinary Medicine have made an ... for treating Ichthyophthirius multifiliis, or "Ich", a devastating ... With the aid of whole-genome sequencing, researchers ... bacteria: Bacteroides, which are usually found free-living, ...
Cached Biology News:Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2Study finds logging effects vary based on a forest's history, climate 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Yeast tRNA 50 l...
Human monocyte-derived dendritic cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Biology Products: